Table 1 Patient characteristics
Median age | 52.5 (23–74) | Treatment | |
|---|---|---|---|
Menoposal status | Neoadjuvant chemotherapy | 11 (22.5%) | |
premenopausal | 21 (42.9%) | Adjuvant chemotherapy | 32 (65.3%) |
postmenopausal | 28 (57.1%) | Recurrence chemotherapy | 6 (12.2%) |
ECOG performance | Combined therapy | ||
0 | 48 (98.0%) | Trastuzumab | 27 (55.1%) |
1 | 1 (2.0%) | Bevasizumab | 6 (12.2%) |
Dominant hand | No combined therapy | 16 (32.7%) | |
R | 48 (98.0%) | History of chemotherapy | |
L | 1 (2.0%) | No | 20 (40.8%) |
Glove size(control side) | Yes | 29 (59.2%) | |
5.5 | 17 (73.9%) | Previous chemotehrapy regimen | |
6.0 | 23 (46.9%) | Anthracyclin based | 28 (57.1%) |
6.5 | 9 (18.4%) | Docetaxel | 1 (2.0%) |
Location of primary tumor | Smoking status | ||
R | 18 (36.7%) | Never smoker | 36 (73.5%) |
L | 30 (61.2%) | Current smoker | 3 (6.1%) |
Bilateral | 1 (2.0%) | Former smoker | 6 (12.2%) |
Axillary dissection | Unknown | 4 (8.2%) | |
No | 26 (55.3%) | Diabetes | |
Yes | 21 (44.7%) | No | 45 (91.8%) |
Subtype of the primary tumor | Yes | 4 (8.2%) | |
ER+/HER2- | 11 (22.9%) | ||
ER+/HER2+ | 18 (37.5%) | ||
ER−/HER2+ | 8 (16.7%) | ||
ER−/HER2- | 11 (22.9%) |